Cargando…

A randomized trial of icosapent ethyl in ambulatory patients with COVID-19

The coronavirus disease 2019 (COVID-19) pandemic remains a source of considerable morbidity and mortality throughout the world. Therapeutic options to reduce symptoms, inflammatory response, or disease progression are limited. This randomized open-label trial enrolled 100 ambulatory patients with sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosmopoulos, Andrew, Bhatt, Deepak L., Meglis, Gus, Verma, Raj, Pan, Yi, Quan, Adrian, Teoh, Hwee, Verma, Maya, Jiao, Lixia, Wang, Robert, Juliano, Rebecca A., Kajil, Mahesh, Kosiborod, Mikhail N., Bari, Basel, Berih, Abdullahi A., Aguilar, Mallory, Escano, Antonnette, Leung, Andrew, Coelho, Idelta, Hibino, Makoto, Díaz, Rafael, Mason, R. Preston, Steg, Ph. Gabriel, Simon, Tabassome, Go, Alan S., Ambrosy, Andrew P., Choi, Richard, Kushner, Arthur M., Leiter, Lawrence A., Al-Omran, Mohammed, Verma, Subodh, Mazer, C. David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388138/ https://www.ncbi.nlm.nih.gov/pubmed/34462732 http://dx.doi.org/10.1016/j.isci.2021.103040

Ejemplares similares

The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Wang, Xiaowen, et al.
Publicado: (2020)

Impact of diabetes duration on left ventricular mass regression with empagliflozin
por: Moroney, Michael, et al.
Publicado: (2023)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
por: Peterson, Benjamin E., et al.
Publicado: (2020)

Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin
por: Puar, Pankaj, et al.
Publicado: (2023)

The Impact of Statins on Postdischarge Atrial Fibrillation After Cardiac Surgery: Secondary Analysis from a Randomized Trial
por: Hibino, Makoto, et al.
Publicado: (2022)

Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial
por: Barbour, William, et al.
Publicado: (2023)

Loss of endothelial cell-specific autophagy-related protein 7 exacerbates doxorubicin-induced cardiotoxicity
por: Luu, Albert Z., et al.
Publicado: (2021)

The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
por: Steg, Ph Gabriel, et al.
Publicado: (2021)

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
por: Peterson, Benjamin E., et al.
Publicado: (2022)

Stage‐based approach to predict left ventricular reverse remodeling after mitral repair
por: Hibino, Makoto, et al.
Publicado: (2022)

Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
por: Garg, Vinay, et al.
Publicado: (2020)

Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria
por: Verma, Subodh, et al.
Publicado: (2023)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
por: Puar, Pankaj, et al.
Publicado: (2023)

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada
por: Lachaine, Jean, et al.
Publicado: (2023)

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT
por: Selvaraj, Senthil, et al.
Publicado: (2022)

Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
por: Miller, Michael, et al.
Publicado: (2022)

Subclinical Valve Thrombosis in Sutureless Bioprosthetic Valves
por: Yanagawa, Bobby, et al.
Publicado: (2017)

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
por: Olshansky, Brian, et al.
Publicado: (2023)

Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014)

Icosapent ethyl: scientific and legal controversies
por: Curfman, Gregory, et al.
Publicado: (2021)

Role of Endothelium in Doxorubicin-Induced Cardiomyopathy
por: Luu, Albert Z., et al.
Publicado: (2018)

Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes: Translational Insights Into the Prevention of Ischemic Complications in Diabetes
por: Terenzi, Daniella C., et al.
Publicado: (2018)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Endothelial cell control of thrombosis
por: Yau, Jonathan W., et al.
Publicado: (2015)

Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical Trial
por: Ha, Andrew C. T., et al.
Publicado: (2021)

Clinical results and mechanism of action of icosapent ethyl
por: Borghi, Claudio, et al.
Publicado: (2023)

Suboptimal use of risk reduction therapy in peripheral arterial disease patients at a major teaching hospital
por: Al-Omran, Mohammed, et al.
Publicado: (2011)

Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
por: Weintraub, William S., et al.
Publicado: (2022)

Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials
por: Verma, Subodh, et al.
Publicado: (2015)

Investigation of TGFβ1-Induced Long Noncoding RNAs in Endothelial Cells
por: Singh, Krishna K., et al.
Publicado: (2016)

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
por: Kosiborod, Mikhail N., et al.
Publicado: (2022)

SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials
por: Dhingra, Nitish K., et al.
Publicado: (2021)

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
por: Scherer, Daniel J, et al.
Publicado: (2015)

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
por: Parhofer, Klaus G, et al.
Publicado: (2020)

Icosapent Ethyl (Vascepa®) for the Treatment of Acute, Severe Pancreatitis
por: Berger, Amnon A, et al.
Publicado: (2020)

Predictors of mitral valve haemodynamics after mitral valve repair for degenerative mitral regurgitation
por: Rumman, Rawan K, et al.
Publicado: (2023)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
por: Pandey, Arjun K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u1a7roj4f5n794h88i80do0ibp